Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement
Klimek, L.; Jutel, M.; Akdis, C.; Bousquet, J.; Akdis, M.; Bachert, C.; Agache, I.; Ansotegui, I.; Bedbrook, A.; Bosnic-Anticevich, S.; Canonica, G. W.; Chivato, T.; Cruz, A. A.; Czarlewski, W.; Giacco, S. D.; Du, H.; Fonseca, J. A.; Gao, Y.; Haahtela, T.; Hoffmann-Sommergruber, K.; Ivancevich, J. C.; Khaltaev, N.; Knol, E. F.; Kuna, P.; Larenas-Linnemann, D.; Melen, E.; Mullol, J.; Naclerio, R.; Ohta, K.; Okamoto, Y.; O'Mahony, Liam; Onorato, G. L.; Papadopoulos, N. G.; Pawankar, R.; Pfaar, O.; Samolinski, B.; Schwarze, J.; Toppila-Salmi, S.; Shamji, M. H.; Ventura, M. T.; Valiulis, A.; Yorgancioglu, A.; Matricardi, P.; Zuberbier, T.; ARIA-MASK Study Group
Date:
2020-04-24
Copyright:
© 2020, John Wiley & Sons, Inc. This is the peer reviewed version of the following article: Klimek, L., Jutel, M., Akdis, C., Bousquet, J., Akdis, M., Bachert, C., Agache, I., Ansotegui, I., Bedbrook, A., Bosnic-Anticevich, S., Canonica, G. W., Chivato, T., Cruz, A. A., Czarlewski, W., Giacco, S. D., Du, H., Fonseca, J. A., Gao, Y., Haahtela, T., Hoffmann-Sommergruber, K., Ivancevich, J. C., Khaltaev, N., Knol, E. F., Kuna, P., Larenas-Linnemann, D., Melen, E., Mullol, J., Naclerio, R., Ohta, K., Okamoto, Y., O'Mahony, L., Onorato, G. L., Papadopoulos, N. G., Pawankar, R., Pfaar, O., Samolinski, B., Schwarze, J., Toppila-Salmi, S., Shamji, M. H., Ventura, M. T., Valiulis, A., Yorgancioglu, A., Matricardi, P., Zuberbier, T. and the ARIA-MASK Study Group (2020) 'Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement', Allergy, doi: 10.1111/all.14336, which has been published in final form at https://doi.org/10.1111/all.14336. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Full text restriction information:
Access to this article is restricted until 12 months after publication by request of the publisher.
Restriction lift date:
2021-04-24
Citation:
Klimek, L., Jutel, M., Akdis, C., Bousquet, J., Akdis, M., Bachert, C., Agache, I., Ansotegui, I., Bedbrook, A., Bosnic-Anticevich, S., Canonica, G. W., Chivato, T., Cruz, A. A., Czarlewski, W., Giacco, S. D., Du, H., Fonseca, J. A., Gao, Y., Haahtela, T., Hoffmann-Sommergruber, K., Ivancevich, J. C., Khaltaev, N., Knol, E. F., Kuna, P., Larenas-Linnemann, D., Melen, E., Mullol, J., Naclerio, R., Ohta, K., Okamoto, Y., O'Mahony, L., Onorato, G. L., Papadopoulos, N. G., Pawankar, R., Pfaar, O., Samolinski, B., Schwarze, J., Toppila-Salmi, S., Shamji, M. H., Ventura, M. T., Valiulis, A., Yorgancioglu, A., Matricardi, P., Zuberbier, T. and the ARIA-MASK Study Group (2020) 'Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement', Allergy. doi: 10.1111/all.14336
Abstract:
The current COVID-19 pandemic influences many areas of social life, medical treatments and the way allergy is performed. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on immunological effects on the diseased patient.
Show full item record
